Jpmorgan Chase & CO Dermata Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

  • $1.22 Trillion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 11, 2022
SELL
$115.2 - $319.2 $65,548 - $181,624
-569 Closed
0 $0
Q1 2022

May 11, 2022
SELL
$223.2 - $571.2 $2.58 Million - $6.61 Million
-11,568 Reduced 95.31%
569 $1,000
Q4 2021

Feb 10, 2022
BUY
$374.4 - $1500.0 $4.54 Million - $18.2 Million
12,137 New
12,137 $21,000

Others Institutions Holding DRMA

# of Institutions
1
Shares Held
0
Call Options Held
0
Put Options Held
0
View Full List

About Dermata Therapeutics, Inc.

DRMA Quotes by TradingView
  • Ticker DRMA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 10,102,200
  • Market Cap $13.5M
  • Description
  • Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe ...
More about DRMA
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email